Tucatinib

Tukysa (tucatinib) is a small molecule pharmaceutical. Tucatinib was first approved as Tukysa on 2020-04-17. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and neoplasm metastasis. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2 and receptor tyrosine-protein kinase erbB-3. In addition, it is known to target epidermal growth factor receptor and receptor tyrosine-protein kinase erbB-4. Tukysa's patents are valid until 2032-10-12 (FDA).